✦ LIBER ✦

Hormone-refractory prostate cancer: what have we learned?

✍ Scribed by Manfred P. Wirth

Book ID: 109053328
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 113 KB
Volume: 100
Category: Article
ISSN: 1464-4096
DOI: 10.1111/j.1464-410x.2007.06957.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The finasteride prostate cancer preventi

The finasteride prostate cancer prevention trial (PCPT) – What have we learned?

✍ J. Kilian Mellon 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 191 KB

Intraoperative Parathyroid Hormone Testi

Intraoperative Parathyroid Hormone Testing: What Have We Learned?

✍ Matthew D. Proctor; Robert A. Sofferman 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB

Breast cancer 1985: What have we learned

Breast cancer 1985: What have we learned?

✍ Jerome A. Urban 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 1006 KB

A popular misconception infers that all breast cancers are systemic from their inception, that variations of primary therapy will not affect prognosis, and that an effective systemic therapy is already available. This is not so. Moderate improvement in long-term survival of breast cancer patients ha

What have we learned?

✍ Robert U. Ayres 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 36 KB

What Have We Learned?

✍ FRED H. FRANKEL 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 324 KB

Bisphosphonates in Hormone-Refractory Pr

Bisphosphonates in Hormone-Refractory Prostate Cancer: Do We Have a Toxicity Problem?

✍ Noel W. Clarke 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 71 KB